Momenta Pharmaceuticals Stock Price - MNTA

Best deals to access real time data!
Real-Time Alerts for Volume Breakouts, Highs and Lows for NYSE, NASDAQ, Amex, OTC Markets and OTCBB
Monthly Subscription
for only
DDE w/Realtime (Monthly)
Monthly Subscription
for only
Big Cap Pro
Monthly Subscription
for only
VAT not included
After Hours
Last Trade
Last $ 28.59 ◊ 0.00 (0.00%)
Company Name Stock Ticker Symbol Market Type
Momenta Pharmaceuticals Inc MNTA NASDAQ Common Stock
  Price Change Change Percent Stock Price High Price Low Price Open Price Close Price Last Traded
  -0.285 -0.99% 28.585 29.43 28.49 28.98 28.87 23:59:39
Bid Price Ask Price Spread Spread % News
12.05 31.15 19.10 61.32% 6 -
Stock Trades Traded Volume VWAP Dollar Volume Average Volume 52 Week Range
10,222 786,429 $ 29.01 $ 22,812,295 1,611,897 9.51 - 31.90
Last Trade Time Type Quantity Stock Price Currency
16:36:43 formt 689 $ 28.585 USD

Momenta Pharmaceuticals Financials

Market Cap Shares in Issue Profit/Loss Earnings Per Share (EPS) PE Ratio Float
$ 2.83B 99.02M $ -176.06M -2.25 - 94.84M
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - 0.00% - -

more financials information »

Momenta Pharmaceuticals News

Loading Messages....

Latest MNTA Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical MNTA Price Data

Period † Open High Low VWAP Avg. Daily Vol Change %
1 Week28.4431.9027.5029.393,170,0300.1450.51%
1 Month20.4231.9018.5024.511,666,9178.1739.99%
3 Months15.7431.9014.6620.421,162,16212.8581.61%
6 Months9.6231.909.5117.88766,55518.97197.14%
1 Year12.1131.909.5116.05632,97916.48136.04%
3 Years14.3032.209.5116.54696,47314.2999.9%
5 Years11.9532.207.8616.14672,71216.64139.21%

Momenta Pharmaceuticals Description

Momenta is a biotechnology company focused on the characterization and development of innovative drugs in autoimmune diseases. Its legacy business includes complex generic versions of MS drug Copaxone and anticoagulant Lovenox, and it receives royalties for these products through a partnership with Novartis. While biosimilar versions of Humira and Eylea are in the pipeline, Momenta terminated future development in generics/biosimilars in 2018. Several innovative drugs, including M281, M254, and M230, are in development to treat rare autoimmune diseases.

Your Recent History
Gulf Keyst..
FTSE 100
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.